Tuesday Morning Corp. stock price, TUES

Tuesday Morning Corp. stock chart:

Tuesday Morning Corp. close price: 3.3

Stock price forecast:

UP TO +4.85%
Target: 3.46

Total forecasts: 81
Reached: 19 (23.46%)

Total Win: 5.35 (156.66%)

DaysForecastsReached%Reached points%InvestedUnreached%Total%

Showing 1-10 of 523 items.
Date of ForecastStock PriceTarget PriceForecast Reached Date

Tuesday Morning Corp. latest news:

  • 03/07/2017 09:41:59

    Wall Street pares losses as techs offset pharma decline

    (Reuters) - U.S. stocks pared losses late Tuesday morning as a decline in drug stocks, triggered by President Donald Trump's tweet about lowering drug prices, was countered by gains in technology shares.

  • 02/28/2017 09:46:02

    Apple stock target boosted to $151 at UBS

    Apple Inc. stock scored another price-target increase Tuesday as enthusiasm surrounding the iPhone 8 continues to grow. UBS increased its 12-month target on Apple shares to $151 from $138 and reiterated a buy rating. In a note to clients, UBS's Steve Milunovich said he believed augmented reality, which could be a new feature unleashed in September with the next-generation iPhone, "could be a boost to Apple" long term. This comes after Apple CEO Tim Cook touted augmented reality in a recent interview with a U.K. newspaper, calling it a “huge” market that could potentially shake up the consumer device industry as much as the smartphone did. Also this week, Mizuho Securities increased its Apple stock target to $150 from $135. Shares of Apple gained 0.3% to $137.30 in late-morning trade. They've increased 23% in the past three months and nearly 42% in the past year, hitting all-time records this month. The Dow Jones Industrial Average , a 30-member index that includes Apple, is up 9% in the past three months and 25.2% in the past year. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 02/21/2017 09:14:20

    UPDATED: EyeGate Pharma surges 49% on news of $4 million Valeant licensing agreement

    EyeGate Pharmaceuticals Inc. shares surged nearly 50% in morning trade Tuesday after an announcement of the company's $4 million licensing agreement with Valeant Pharmaceuticals International Inc. . The deal is for exclusive, global commercial and manufacturing rights for EyeGate's EyeGate II Delivery System, which is an alternative to eye drops and ocular injections, and EGP-437 combination product, which is being developed for post-operative pain and inflammation in patients who've had ocular surgery. The deal consists of cash upfront for EyeGate, and up to $99 million in potential milestone payments and royalties on Valeant's net sales of the product, according to an EyeGate Securities and Exchange Commission filing. Valeant had previously licensed the same product, EGP-437, from EyeGate for uveitis in 2015. EyeGate reported positive results from a early/mid-stage trial in December. Valeant shares lifted 1.3% in Tuesday morning trade. Valeant shares have dropped 11.4% over the last three months, and EyeGate shares have risen 35.3%, compared with a 7.5% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 02/07/2017 10:20:08

    Cardinal Health profit beats estimates on lower costs

    Cardinal Health Inc(CAH) reported a better-than-expected quarterly profit on Tuesday helped by lower costs and tax rate even as the drug distributor faced generic pricing pressure. Shares of the company, which also cut its 2017 forecast for adjusted earnings from continuing operations, were up 3.8 percent at $78.88 in morning trading.

  • 02/06/2017 22:18:00

    Nikkei Hits 2-Week Low Ahead of Abe-Trump Talks

    Japan's Nikkei share average dropped to a two-week low on Tuesday morning after global stocks fell and a stronger yen hurt overall sentiment.

  • 01/24/2017 03:09:47

    Pound bounces around $1.25 after U.K. Supreme Court rejects government's Brexit appeal

    The pound was sent on a rollercoaster ride in Tuesday morning trade after the U.K.'s Supreme Court ruled that the government can't trigger the Article 50 that starts the Brexit process without approval from parliament. The court also said Prime Minister Theresa May won't have to ask the devolved governments -- Scotland, Northern Ireland and Wales -- before kicking off the exit negotiations. Sterling initially rose to $1.2534 after the decision was announced, but quickly turned lower to trade at $1.2475. The pound exchanged hands at $1.2536 late Monday in New York. "We have seen the initial move for sterling mainly towards the upside, but as the dust settled, we have seen the sterling giving up all those gains," said Naeem Aslam, chief market analyst at ThinkForex, in a note. "This is mainly because the market believes that Brexit will move forward now. Moreover GBP was pricing in regionalized government being consulted and the Supreme Court has said that they do not need to be involved in," he added. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    Tuniu CorporationTOUR | Turtle Beach CorporationHEAR | Tuttle Tactical Management Multi-Strategy Income ETUTI | Tuttle Tactical Management U.S. Core ETFTUTT | Twenty-First Century Fox, Inc.FOX | Twenty-First Century Fox, Inc.FOXA | Twin Disc, IncorporatedTWIN | Two River BancorpTRCB | U S Concrete, Inc.USCR-0.78% | U.S. Auto Parts Network, Inc.PRTS |